Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ketek 24,000-Patient Trial Should Be New “Benchmark” For Antibiotics

Executive Summary

Aventis' 24,000-patient "usual care" study for Ketek should be the benchmark for investigational antibiotic safety trials, FDA Anti-Infective Drugs Advisory Committee voting consultant William Lee, MD, University of Texas Southwestern Medical School, said Jan. 8

You may also be interested in...



Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin

Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal

Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin

Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal

Legislation On CROs And IRBs Might Be One Fall-Out From Ketek Probe

The House Energy and Commerce Committee is considering the need for legislation to set new parameters for organizations involved in drug development. Their concern is prompted by the failure of individuals overseeing safety study 3014 for Sanofi-Aventis' Ketek (telithromycin) to report investigator misconduct to FDA

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel